Login to Your Account



In The Clinic NEWS

While Sarepta Therapeutics Inc. waits for the FDA's decision on its DMD candidate, eteplirsen, Marathon Pharmaceuticals LLC is quickening its pace in the race to approval in the field.

Nearly six months after downsizing, in part to focus on gaining regulatory approvals for its ALK inhibitor brigatinib, Ariad Pharmaceuticals Inc. has completed a rolling submission of a new drug application for the candidate.

Top-line data from CTI Biopharma Corp.'s phase III trial of pacritinib, a JAK2/FLT3 multikinase inhibitor for high-risk patients with advanced myelofibrosis showed the treatment demonstrated statistically significant improvement in spleen volume reduction vs. best available treatment.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: